title: Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo.
abstract: The safety, stability, and ability for repeat homologous vaccination makes the DNA vaccine platform an excellent candidate for an effective HIV-1 vaccine. However, the immunogenicity of early DNA vaccines did not translate from small animal models into larger non-human primates and was markedly lower than viral vectors. In addition to improvements to the DNA vector itself, delivery with electroporation, the inclusion of molecular adjuvants, and heterologous prime-boost strategies have dramatically improved the immunogenicity of DNA vaccines for HIV and currently makes them a leading platform with many areas warranting further research and clinical development.
authors.affiliation: Department of Pathology and Laboratory Medicine, Perlman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.
authors.forename: Natalie A
authors.initials: NA
authors.lastname: Hutnick
authors.forename: Devin J F
authors.initials: DJ
authors.lastname: Myles
authors.forename: Chaoran Billie
authors.initials: CB
authors.lastname: Bian
authors.forename: Karuppiah
authors.initials: K
authors.lastname: Muthumani
authors.forename: David B
authors.initials: DB
authors.lastname: Weiner
mesh_terms: D016915:AIDS Vaccines / Q000235:genetics / Q000276:immunology*; D000818:Animals; D015658:HIV Infections / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D014611:Vaccination / Q000379:methods*; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D019444:Vaccines, DNA